CytomX Therapeutics, Inc. announced encouraging interim results from its Phase 1 study of CX-2051, an EpCAM-directed antibody-drug conjugate ... Of those trades, 0 have been purchases and 5 ...

In January, we made some ... things have been progressing extremely well. We're ahead of our timeline and learning much about how to deal with sites, how to make the drug available, et cetera.

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other worst blue ...

Kennedy Jr. said the timeline to see U.S. drug prices ... "But we've been meeting with the pharmaceutical companies. They admit that this is something that should have ended a long time ago ...

President makes push to bring down drug prices that have long been a source of financial strain ... greedy pharmaceutical industry made over $100bn in profits last year by ripping off the American ...

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

The FDA has ... of Regeneron’s ANGPTL3-targeting antibody evinacumab for a rare, inherited disorder that dramatically raises the risk of heart disease. The cholesterol-lowering drug has been ...

It has been an amazing start to the season for the ... There were only six players, including Greene, 23 years old or younger who made the All-Star team, showing that he belongs in the ...

His analysis can lean more toward entertaining than insightful, but the way he can deliver lines on the air has made Smith a prominent figure in American media. It's no surprise, then, that he's ...

Regeneron and Teva ... who currently have very limited therapeutic choices to treat their chronic pain, other than with non-steroidal anti-inflammatory drugs or opioids.” Earlier this year ...

There’s also been a sense of whiplash from ... Once the two countries have satisfied Trump’s demands on immigration and drug trafficking, the White House adds, the tariff on the rest of ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference.